Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 100,900 shares, an increase of 41.3% from the July 15th total of 71,400 shares. Currently, 0.4% of the company’s shares are short sold. […]
Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 100,900 shares, a growth of 41.3% from the July 15th total of 71,400 shares. Based on an average daily volume of 69,100 shares, […]
Silence Therapeutics plc (NASDAQ:SLN – Free Report) – Analysts at William Blair issued their Q1 2024 EPS estimates for Silence Therapeutics in a report released on Thursday, August 3rd. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.46) per share for the quarter. The consensus estimate for Silence Therapeutics’ current […]
Morgan Stanley reaffirmed their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $20.00 price objective on the stock. Silence Therapeutics Stock Up 0.4 % NASDAQ SLN opened at $5.38 on Monday. The firm has a market cap of $161.02 […]
Silence Therapeutics (OTCMKTS:SLNCF – Get Free Report) is one of 383 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Silence Therapeutics to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk. Insider & Institutional Ownership 7.9% of […]